P-21

P-21 is a synthetic modified tetrapeptide developed at the New York State Institute for Basic Research in Developmental Disabilities by Khalid Iqbal and colleagues. The sequence is acetyl-Asp-Gly-Gly-Leu-amide (Ac-DGGL-NH2) with an adamantane stabilization group, giving a molecular weight of 578.3 g/mol. The compound was designed as a peptide mimetic of ciliary neurotrophic factor (CNTF), small enough to cross the blood-brain barrier and resist enzymatic degradation. Evidence is preclinical-dominant. No published human clinical trial exists.

The compound has a tangled name history. "P-21" or "P021" refers to this CNTF-derived neurotrophic peptide. The same designation is sometimes confused with the cyclin-dependent kinase inhibitor p21 (CDKN1A), which is an unrelated cell-cycle regulator protein. Some research-chemical vendor sites still propagate the confused naming. The compound described here is the Iqbal-group neurotrophic tetrapeptide, also called Peptide 021 or Peptide 6.

The development pathway began with epitope mapping of Cerebrolysin, a porcine brain-derived peptide mixture with established use in stroke and dementia care in some European countries. The Iqbal group identified the most active short-peptide fragments responsible for Cerebrolysin's neurogenic effects, then synthesized stabilized analogs designed to retain the neurotrophic activity while improving pharmacokinetic properties. P-21 emerged as the lead compound from that effort. Animal model studies followed through the 2010s.

The Animal Evidence

The compound has been tested in multiple transgenic mouse models of Alzheimer's disease:

Tau pathology rescue (Kazim et al., 2014). Treatment of 3xTg-AD mice with P-21 reduced tau hyperphosphorylation, decreased markers of synaptic pathology, and improved cognitive performance on memory tasks.

Spatial learning recovery (Khatoon et al., 2015). P-21 treatment rescued spatial learning and memory deficits in adult AD-model mice. Hippocampal neurogenesis markers were elevated in treated animals.

Synaptic deficit prevention (Baazaoui and Iqbal, 2017). Long-term P-21 treatment in 3xTg-AD mice prevented age-associated synaptic and cognitive deficits, indicating disease-modifying rather than purely symptomatic effects.

Mechanism work (Bolognin et al., 2014). Documented effects on BDNF expression, dendritic complexity, and hippocampal neurogenesis in treated AD-model mice.

The cumulative animal dataset is substantial within the model system used. The published work is concentrated in the Iqbal group and collaborators, which raises the standard concern about independent replication that applies to many preclinical peptide development programs.

The Human Evidence

There is none.

No registered clinical trial of P-21 exists in ClinicalTrials.gov. No Phase 1 safety data has been published in peer-reviewed form. The compound has not progressed to human dose-finding or proof-of-concept testing as of May 2026, despite more than a decade of positive preclinical work.

The reasons for the gap between preclinical promise and human development are not publicly documented in detail. Translation of neurotrophic peptide candidates from rodent models to human Alzheimer's disease has a long history of failure. Full-length CNTF itself (Axokine, developed by Regeneron) produced dose-limiting toxicity, immunogenicity, and weight loss that ended its development. P-21's design as a small peptide mimetic was intended to avoid those liabilities. Whether the compound would translate the rodent benefits without acquiring new translation problems is not known.

Regulatory and Legal Status

FDA. No approval. No IND filing visible in public records as of May 2026.

EMA. No approval.

Compounding. Not on the FDA bulk drug substances list.

WADA. Not on the 2026 Prohibited List.

Research-chemical availability. Sold by several vendors as lyophilized powder. Identity and purity verification is the buyer's responsibility.

The proposed mechanism is indirect modulation of neurotrophic signaling rather than direct CNTF receptor agonism.

LIF signaling inhibition. Leukemia inhibitory factor (LIF) is a member of the IL-6 cytokine family that suppresses neurogenesis in adult hippocampus. P-21 partially inhibits LIF signaling, removing a suppressor of neurogenesis and allowing increased differentiation of neural progenitor cells in the dentate gyrus.

BDNF upregulation. Treated animals show elevated brain-derived neurotrophic factor expression in hippocampus. BDNF is a major driver of synaptic plasticity, memory consolidation, and adult neurogenesis. The mechanism by which P-21 elevates BDNF is partly through LIF pathway modulation and partly through direct effects on neurotrophic signaling cascades.

GSK-3 beta modulation. Animal data has documented reduced GSK-3 beta activity in treated brains, with downstream reduction in tau hyperphosphorylation. This connects the cognitive-rescue effects with reduction of Alzheimer's-relevant pathology.

Adult hippocampal neurogenesis. Treated rodents show increased markers of dentate gyrus neurogenesis (DCX-positive cells, BrdU incorporation, mature neuron differentiation). The increase is mechanistically linked to LIF inhibition and BDNF elevation.

Pharmacokinetics. The adamantane modification was added to improve metabolic stability and brain penetrance. Acetylation and amidation block N- and C-terminal protease degradation. The combined modifications extend half-life and improve oral and intranasal bioavailability compared with unmodified DGGL. Specific human pharmacokinetic data is not published because the compound has not entered human trials.

Human pharmacokinetic data is not published.

Animal-model effects documented in published work:

• Rescue of spatial learning and memory in transgenic AD mice
• Reduction in tau hyperphosphorylation and tangle pathology
• Increased hippocampal neurogenesis
• Improved dendritic complexity and synaptic density
• Disease-modifying effects in long-term dosing studies
• Effects in both early and late intervention paradigms in AD models

Research-chemical user reports outside investigational settings describe:

• Subjective improvement in mood and cognitive sharpness
• Perceived enhancement in verbal fluency and creative thought
• Reports of vivid dreams and altered sleep architecture
• No serious adverse events reported in informal user community contexts

User reports are anecdotal, uncontrolled, and not verified for vial identity or dose accuracy. They constitute the weakest tier of evidence and should not be treated as data.

No standardized human dosing protocol exists for P-21 because no human clinical trial has been published.

Rodent studies have used subcutaneous, intraperitoneal, and intranasal routes. The Baazaoui and Iqbal long-term work used chronic dosing over 6 to 18 months in mice at doses that scale unclearly to human equivalents.

Research-chemical user protocols typically use:

• Subcutaneous injection at 100 to 500 mcg per day
• Intranasal administration at 500 mcg to 1 mg per day
• Cycle lengths of 4 to 6 weeks with breaks between cycles

These doses are extrapolated from rodent body-surface-area scaling and informal community experience. They are not supported by clinical pharmacokinetic data. The compound's small molecular weight, lipid-friendly adamantane modification, and intranasal delivery option suggest reasonable brain bioavailability, but actual human plasma and CSF concentrations after standard research-chemical doses have not been measured in published studies.

Animal toxicology has not flagged dose-limiting toxicity in rodent studies up to 18 months at the doses tested. The compound has not produced the weight loss, immunogenicity, or local injection reactions that ended full-length CNTF (Axokine) clinical development.

Long-term human safety data does not exist. The compound has not entered Phase 1 trials.

Theoretical concerns based on mechanism and class:

• Effects on neural circuit homeostasis with chronic high-dose neurogenesis stimulation are unknown
• Seizure threshold effects from sustained BDNF elevation could in principle become relevant at chronic high doses
• Effects on tissues outside CNS that express CNTF or LIF receptors have not been comprehensively mapped
• Drug-drug interactions with antidepressants, antiepileptics, or other CNS-active medications have not been studied

These concerns are mechanistic flags that would normally be addressed in Phase 1 safety studies, which have not occurred.

P-21 is most often compared with its parent compound Cerebrolysin. Cerebrolysin is a porcine-brain-derived peptide mixture with established clinical use in some European countries for stroke and dementia. P-21 is the defined single-molecule fragment derived from Cerebrolysin's active components by epitope mapping. The two compounds offer different trade-offs: Cerebrolysin has broader claimed effects from its peptide mixture, P-21 offers a more focused mechanism with defined molecular identity.

For nootropic stacking, P-21 is often combined with Semax or Selank for broader cognitive coverage, or with Dihexa (a hepatocyte-growth-factor-mimetic angiotensin IV analog with similar neurogenic claims). None of these combinations has been studied in controlled human trials.

For external comparators in the Alzheimer's disease therapeutic landscape, the established categories include cholinesterase inhibitors (donepezil, rivastigmine, galantamine), NMDA antagonists (memantine), and the newer amyloid-targeting antibodies (lecanemab, donanemab). These have FDA-approved indications based on Phase 3 trial evidence. P-21 has no human trial evidence and is not a substitute for any of these therapies in clinical AD management.

The compound's main interest is mechanistic and preclinical: a defined small peptide with documented effects on adult hippocampal neurogenesis and tau pathology in rodent AD models. The translation gap to humans is large and has not been closed by the development program over more than a decade.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.